Syllabus
Gene therapy (history, main principles, current trends)
Immunotherapy and cell therapy (history, main principles, current trends)
Modern targeted/controlled drug delivery systems (history, main principles, current trends)
Trends in personalized therapy and "omics" methods
Current strategies in cancer therapy(newly identified targets, their use, application of new therapeutic approaches)
Immunotherapy of allergy, experimental immunomodulation and stem cells (newly identified targets, application of new therapeutic approaches)
Current strategies in the therapy of leukemias and autoimmune diseases (newly identified targets, application of modern therapeutic approaches)
Annotation
Intensive scientific progress over the last two decades has helped to identify the molecular basis of many diseases in increasing detail and to define new targets for treatment. This progress has logically stimulated the development of modern pharmacotherapeutic strategies that target newly identified molecular structures and thus significantly complement the conventional drugs and therapeutic approaches used to date.
Basic information about current drugs, their mechanisms of action and application in clinical practice is provided to students in the profile subject Pharmacology. However, due to the complexity of the content, it is not possible to provide sufficient space in these courses for the elucidation of new therapeutic approaches and a more detailed description of current trends in pharmacotherapy and the development of new drugs.
The subject Current Strategies in Pharmacotherapy offers students the opportunity to learn about an area that is shaping the future direction of human medicine. The aim of the subject is to enable students to orient themselves in the following areas: 1) modern therapeutic strategies and their application in clinical practice and 2) new molecular targets of drug action and their implementation in the pharmacotherapy of major diseases.
Erudition in this area will help them to successfully enter practice, not only in companies or R&D-oriented institutions.